Results 1 to 10 of about 127,348 (379)

Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort [PDF]

Viruses, 2022
Vaccines are the most effective means to prevent the potentially deadly effects of SARS-CoV-2 infection, but not all vaccinated individuals gain the same degree of protection.
Erika Zecca, Manuela Rizzi, Stelvio Tonello, Erica Matino, Martina Costanzo, Eleonora Rizzi, Giuseppe Francesco Casciaro, Giulia Francesca Manfredi, Antonio Acquaviva, Ileana Gagliardi, Elisa Calzaducca, Venkata Ramana Mallela, Davide D’Onghia, Rosalba Minisini, Mattia Bellan, Luigi Mario Castello, Francesco Gavelli, Gian Carlo Avanzi, Filippo Patrucco, Annalisa Chiocchetti, Mario Pirisi, Cristina Rigamonti, Daniele Lilleri, Daniele Sola, Pier Paolo Sainaghi   +24 more
doaj   +2 more sources

Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases

Vaccines, 2022
The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments.
Maria De Santis, Francesca Motta, Natasa Isailovic, Massimo Clementi, Elena Criscuolo, Nicola Clementi, Antonio Tonutti, Stefano Rodolfi, Elisa Barone, Francesca Colapietro, Angela Ceribelli, Matteo Vecellio, Nicoletta Luciano, Giacomo Guidelli, Marta Caprioli, Clara Rezk, Lorenzo Canziani, Elena Azzolini, Luca Germagnoli, Nicasio Mancini, Ana Lleo, Carlo Selmi   +21 more
doaj   +2 more sources

Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial

BMC Cancer, 2020
Background Clinical outcomes of patients with osteosarcoma remain unsatisfactory, with little improvement in a 5-year overall survival over the past three decades.
Nut Koonrungsesomboon, Nuttapong Ngamphaiboon, Natavudh Townamchai, Pimpisa Teeyakasem, Chaiyut Charoentum, Pimlak Charoenkwan, Rungrote Natesirinilkul, Lalita Sathitsamitphong, Touch Ativitavas, Parunya Chaiyawat, Jeerawan Klangjorhor, Suradej Hongeng, Dumnoensun Pruksakorn   +12 more
doaj   +2 more sources

Mycophenolate therapy in interstitial pneumonia with autoimmune features: a cohort study

Therapeutics and Clinical Risk Management, 2018
Sara S McCoy,1 Zubin Mukadam,2 Keith C Meyer,2 Jeffrey P Kanne,3 Cristopher A Meyer,3 Maria D Martin,3 Emmanuel Sampene,4 Scott W Aesif,5 Laurie N Rice,6 Christie M Bartels1 1Division of Rheumatology, Department of Internal Medicine, School of Medicine ...
McCoy SS, Mukadam Z, Meyer KC, Kanne JP, Meyer CA, Martin MD, Sampene E, Aesif SW, Rice LN, Bartels CM   +9 more
doaj   +2 more sources

A generalized fixed drug eruption associated with mycophenolate [PDF]

JAAD Case Reports, 2017
Corey Georgesen, MD, Sarah Lieber, MD, Henry Lee, MD   +2 more
doaj   +2 more sources

Successful long-term treatment of tubulointerstitial nephritis and uveitis with mycophenolate. [PDF]

BMJ Case Rep
Qi L, Chandler S, Puri P, Hepburn K.
europepmc   +3 more sources

Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy

JAMA Network Open, 2023
This randomized clinical trial investigates the risk of kidney outcomes among patients with progressive IgA nephropathy receiving mycophenolate mofetil with supportive care vs supportive care alone.
F. Hou, D. Xie, Jun Wang, Xin Xu, Xiaobing Yang, Jun Ai, S. Nie, M. Liang, Guobao Wang, Nan Jia   +9 more
semanticscholar   +1 more source

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients

American Journal of Transplantation, 2021
Kidney transplant recipients (KTRs) are extremely vulnerable to SARS‐CoV‐2 infection and show an impaired immune response to SARS‐CoV‐2 vaccination. We analyzed factors related to vaccination efficiency in KTRs. In a multicenter prospective observational
Marta Kantauskaite, L. Müller, T. Kolb, Svenja Fischer, J. Hillebrandt, K. Ivens, M. Andrée, Tom Luedde, H. Orth, O. Adams, H. Schaal, C. Schmidt, Eva Königshausen, L. Rump, J. Timm, J. Stegbauer   +15 more
semanticscholar   +1 more source

Stopping of Mycophenolic Acid in Kidney Transplant Recipients for 2 Weeks Peri-Vaccination Does Not Increase Response to SARS-CoV-2 Vaccination—A Non-randomized, Controlled Pilot Study

Frontiers in Medicine, 2022
IntroductionKidney transplant recipients (KTR) are at high risk of developing severe COVID-19. However, vaccine response in this population is severely impaired with humoral response rates of 36–54 and 55–69% after two or three doses of SARS-COV-2 ...
Florina Regele, Andreas Heinzel, Karin Hu, Lukas Raab, Farsad Eskandary, Ingrid Faé, Sieglinde Zelzer, Georg A. Böhmig, Gregor Bond, Gottfried Fischer, Rainer Oberbauer, Roman Reindl-Schwaighofer   +11 more
doaj   +1 more source

Case Report: Azathioprine: An Old and Wronged Immunosuppressant

Frontiers in Immunology, 2022
Mycophenolate rapidly substituted azathioprine (AZA) in transplant immunosuppression regimens since the 1990s, when early clinical trials indicated better outcomes, although opposite results were also observed. However, none of these trials used the well-
Pedro R. Chocair, Precil Diego Miranda de Menezes Neves, Sara Mohrbacher, Maurilio Pacheco Neto, Victor A. H. Sato, Érico S. Oliveira, Leonardo V. Barbosa, Alessandra M. Bales, Fagner Pereira da Silva, Américo L. Cuvello-Neto, John A. Duley   +10 more
doaj   +1 more source